SavedAdd your journal

Journals / E Journal of Cardiovascular Medicine / 2018 / Cilt: 6 - Sayı: 4

The Effect of Heparin on In Vitro Stimulated Platelet Aggregation by Elective Percutaneous Coronary Intervention

Ebru İpek TÜRKOĞLU
Nazan BİTİR
Pages
140–144
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This finding might explain the prothrombotic tendency of heparin, however further investigations are needed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The aim of the present study was to investigate the effects of heparin on in vitro stimulated platelet aggregation by elective percutaneous coronary intervention Methods: Thirty elective percutaneous coronary angioplasty (PTCA) patients were included in the present study.
📊
Key Findings & Data:Two blood samples were obtained during the intervention before and 10 minutes after heparin bolus and stimulated platelet aggregation responses were investigated.
💡
Conclusion & Impact:This finding might explain the prothrombotic tendency of heparin, however further investigations are needed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background: The aim of the present study was to investigate the effects of heparin on in vitro stimulated platelet aggregation by elective percutaneous coronary intervention Methods: Thirty elective percutaneous coronary angioplasty (PTCA) patients were included in the present study. The patients were administered heparin as anticoagulant agent during PTCA. Two blood samples were obtained during the intervention before and 10 minutes after heparin bolus and stimulated platelet aggregation responses were investigated. Results: The difference in platelet aggregation response to adenosine diphosphate (ADP) before and after unfractionated heparin (UFH) was statistically significant (p 0.05). Conclusion: Heparin increases in vitro platelet aggregation stimulated with ADP in elective PTCA patients. This finding might explain the prothrombotic tendency of heparin, however further investigations are needed.

🔖

Cite This Article

TÜRKOĞLU, E. İ., BİTİR, N. (2018). The Effect of Heparin on In Vitro Stimulated Platelet Aggregation by Elective Percutaneous Coronary Intervention. E Journal of Cardiovascular Medicine, Cilt: 6 - Sayı: 4, 140–144. https://ajindex.com/articles/154330

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Mascelli MA, Kleiman NS, Marciniak SJ Jr, Damaraju L, Weisman HF, Jordan RE. Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am Heart J 2000;139:696-703.
  2. Xaio Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-6.
  3. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980;65:64-73. Eika C. Inhibition of thrombin-induced aggregation of human platelets in heparin. Scand J Haematol 1971;8:216-22.
  4. Thomson C, Forbes CD, Prentice CR. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med 1973;45:485- 94. Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975;292:146-51. Eika C. On the mechanism of platelet aggregation induced by heparin, protamine, and polybrene. Scand J Haematol 1972;9:248-57. Eika C. The platelet aggregation effect of eight commercial heparins. Scand J Haematol 1972;9:480-2. Horne MK. Heparin binding to normal and abnormal platelets. Thromb Res 1988;51:135-44.
  5. Goldstad GO, Solumn NO, Krutnes MB. Heparin binding platelet proteins demonstrated by crossed affinity immunoelectrophoresis. Br J Haematol 1983;53:563-6.
  6. Sobel M, Adelman B. Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res 1988;50:815-26.
  7. Holmer E, Lindhal U, Backström G, et al. Anticoagulant activities and effects on platelet of a heparin fragment with high affinity for antithrombin. Thromb Res 1980;18:861-9.
  8. Westwick J, Scully MF, Poll C, Kakkar VV. Comparison of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res 1986;42:435-47.
  9. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
  10. Melina G, Colivicchi F, Bevilacqua E, Mangnanimi S, Melina D. Blood pressure variations, haemorheological determinants, and platelet aggregation in hypertensive patients eith unstable angina. Clin Exp Hypertens 1995;17:1145-56. al-Nozha M, Gader AM, al-Momen AK, Noah MS, Jawaid M, Arafa M. Haemostatic variables